Cybin gears up for registrational trial of psilocybin analog in major depression after PhII success
Cybin’s psychedelic-inspired drug candidate has met the primary endpoint of its mid-stage test in major depressive disorder (MDD), sparking preparations for a Phase III trial set to start enrolling next year.
The Canadian biotech is aiming to enroll 220 patients into the Phase III trial, CEO Doug Drysdale told Endpoints News in an email.
Cybin’s Phase I/IIa study evaluated several doses of its deuterated analog of psilocybin, dubbed CYB003, in 68 people with and without MDD. The MDD subjects had unresponsive moderate-to-severe disease and were on a stable dose of SSRIs. The Phase II portion set CYB003 against placebo in over 30 patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.